PolyPid Ltd. (PYPD) Stock Analysis & Investment Frameworks
PolyPid Ltd. (PYPD) stock analysis on Invetso. Review PolyPid Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
PolyPid Ltd. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
PolyPid Ltd. Key Financial Metrics
- Market Cap: $124.71M
- Revenue: $N/A
- ROE: -311.07%
- ROIC: 11.71%
- Dividend Yield: N/A
About PolyPid Ltd.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
PolyPid Ltd. Investment Frameworks
Invetso analyzes PolyPid Ltd. (PYPD) across the following frameworks:
- PolyPid Ltd. 10Y Growth Potential
- PolyPid Ltd. Scenario Analysis
- PolyPid Ltd. Risks & Opportunities
- PolyPid Ltd. Economic Moat
- PolyPid Ltd. Business Model
- PolyPid Ltd. Management
- PolyPid Ltd. SWOT Analysis
- PolyPid Ltd. Porter's 5 Forces
- PolyPid Ltd. PESTLE Analysis
- PolyPid Ltd. ESG Analysis